Table 2.
Description of the clinical course and individual treatment of SIRT patients.
| Gender | Age | Time to M1 | M1 to SIRT | #lines pre | SIRT resp. | H-PFS | 1stPD post SIRT | #lines post | OS post SIRT | Status | Mutational type |
|---|---|---|---|---|---|---|---|---|---|---|---|
| f | 22 | 55 | 50 | 3 | CR | 21 | HEP at 21 mos | 3 | 87 | DOD | Ex 11 N556_573del + D820Y |
| f | 43 | 10 | 96 | 3 | SD | 33 | OSS at 6 mos | 2 | 33 | DOD | Ex 11 M552-V559del + Y823D |
| m | 39 | 44 | 78 | 4 | PR | 8 | HEP at 8 mos | 2 | 21 | DOD | Ex 11 W557_K558del + Y823C |
| m | 43 | Initial M1 | 128 | 5 | SD | 4 | HEP at 4 mos | 3 | 13 | DOD | Ex 11 31bpdel + D820Y |
| m | 55 | 36 | 7 | 2 | PR | 15 | HEP at 15 mos | 3 | 26 | DOD | Ex 11 w557_558del + V654A |
| m | 53 | Initial M1 | 37 | 2 | PR | 6 | HEP at 6 mos | 2 | 12 | DOD | Ex 11 K558_E562del + N822K |
| f | 39 | Initial M1 | 93 | 4 | PR | 5 | PER at 3 mos | 2 | 7 | DOD | Ex 11 W557_558delins + V654A |
| f | 69 | 41 | 39 | 3 | SD | 4 | PER at 3 mos | 0 | 4 | DOD | Ex 11 W557R |
| m | 68 | 24 | 34 | 3 | SD | 34 | OSS at 20 mos | 3 | 36 | DOD | Ex 11 L576P |
| f | 72 | Initial M1 | 20 | 2 | CR | 6 | HEP + PER at 6mos | 1 | 28 | DOD | Ex 11 W557_559del |
| m | 70 | Initial M1 | 31 | 3 | SD | 4 | HEP at 4 mos. | 2 | 12 | DOD | Ex 11 W557_V559del |
| m | 49 | Initial M1 | 72 | 2 | PR | 15 | HEP at 15 mos | 1 | 21 | DOC# | Ex 11 W557_558Kdel |
| f | 67 | 45 | 13 | 3 | CR | 29 | OSS at 25 mos | 4 | 78 | AWD | Ex 11 dupl 1724_1765 |
| f | 63 | 17 | 107 | 1 | SD* | 22 | PER at 8 mos | 3 | 23 | DOD | Ex 11 K558_V559del |
| m | 65 | Initial M1 | 109 | 3 | SD | 26 | OSS at 3 mos | 3 | 34 | DOD | Ex 11 K550_K558del |
| f | 49 | 10 | 24 | 4 | PR | 13 | PER + STS at 6 mos | 2 | 19 | DOD | Ex 9 Y502_503F ins |
| m | 48 | Initial M1 | 74 | 3 | PR | 7 | HEP + PER at 7mos | 2 | 16 | DOD | Ex 9 Y502_503F ins |
| m | 42 | 48 | 13 | 1 | PR | 30 | HEP at 30 mos | 2 | 147 | AWD | Ex 9 Y502_503F ins |
| f | 42 | 24 | 66 | 4 | SD | 5 | OSS + STS at 4mos | 0 | 10 | DOD | Ex 9 Y502_503F ins |
| m | 65 | Initial M1 | 67 | 4 | PR | 7 | HEP at 7 mos | 2 | 12 | DOD | Ex 13 K642E |
| f | 46 | 6 | 40 | 1 | PR | 16 | PER at 5 mos | 2 | 66 | AWD | PDGFRA Ex 18 D842V |
| m | 68 | 39 | 17 | 4 | PR* | 25 | PER at 15 mos. | 1 | 40 | DOD | qwt |
| f | 46 | 12 | 33 | 1 | PR | 32 | PER at 11 mos | 5 | 77 | AWD | qwt |
| f | 36 | Initial M1 | 10 | 2 | PR | 23 | PER at 3 mos | 4 | 32 | DOD | qwt |
| f | 17 | Initial M1 | 5 | 0 | SD | 41 | 0 | 54 | AWD | Carney Stratakis syndrome | |
| f | 57 | Initial M1 | 5 | 0 | SD | 6 | 0 | 6 | AWD | SDHB-deficiency | |
| *pCR at biopsy | #post-operative lung embolism | ||||||||||
Gender: f female, m male, Age at disease onset in years, Time to M1 time interval after treatment of the primary tumor until the detection of metastatic disease in months, M1 to SIRT duration of metastatic disease from detection to treatment with SIRT in months, #lines pre number of treatment lines prior to SIRT, SIRT resp. result of SIRT according to MRI-imaging. In two patients marked with*, a histological complete remission (pCR) was confirmed after biopsy, H-PFS duration of hepatic progression-free survival (H-PFS) after SIRT in months, 1stPD post SIRT site of first progression after SIRT (HEP hepatic, PER peritoneal, OSS osseous, STS soft tissue), #lines post number of treatment lines after SIRT, OS post SIRT overall survival after SIRT (OS) in months, Status current status of the patients in months, DOC# identifies death from lung embolism, (AWD alive with disease, DOD death of disease, DOC death of other cause), Mutational type mutational status of GIST, the mutation subtype in bold indicates the secondary mutation detected (q-wt quadruple wildtype).